Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This locus identifies a **pseudogene within the aldo-keto reductase (AKR) family**, a superfamily of enzymes that typically catalyze reductions of carbonyl groups to alcohols, but in this case, the sequence is **incapable of encoding a functional protein product**. Pseudogenes are non-functional relatives of protein-coding genes, arising via gene duplication or retrotransposition events, and may retain high sequence similarity but accumulate mutations preventing normal translation or function[1][2][3]. Although AKR pseudogenes can sometimes regulate gene expression by acting as molecular decoys, there is no evidence this locus is involved in such a role. **ENSG00000286064 is not considered a receptor, enzyme, transporter, transcription factor, or traditional drug target**, and the naming is generic, providing no clear connection to validated functional genes or therapeutic relevance. Key points: - **ENSG00000286064** is a pseudogene, not a protein-coding gene, and does not perform enzymatic activity or serve as a drug target[1][2][3]. - The designation "aldo-keto reductase family pseudogene" is nonspecific—many such pseudogenes exist in the human genome, and correct scientific naming typically gives the parent gene (e.g., AKR1C-pseudo)[2][3]. - No clinical relevance, drug interaction, or disease-specific evidence is available for this specific pseudogene. If you need information about specific functional AKR gene members (such as AKR1C2 or AKR1B1), they have well-defined aliases, molecular classification as enzymes, roles in cancer and metabolic diseases, and known inhibitors. However, ENSG00000286064 itself is not such an entity[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aldo-keto reductase family pseudogene.